Effects of isoflurane on the actions of neuromuscular blockers on the muscle nicotine acetylcholine receptors

Abstract

In this study, we tested the hypothesis that volatile anesthetic enhancement of muscle relaxation is the result of combined drug effects on the nicotinic acetylcholine receptors. The poly A m RNA from muscle by isolation were microinjected into Xenopus oocytes for receptor expression. Concentration-effect curves for the inhibition of Ach-induced currents were established for vecuronium, rocuranium, and isoflurane. Subsequently, inhibitory effects of NDMRs were studied in the presence of the isoflurane at a concentration equivalent to half the concentration producing a 50% inhibition alone. All tested drugs produced rapid and readily reversible concentration-dependent inhibition. The 50 inhibitory concentration values were 889 μmol/L (95% CI: 711–1214 μmol). 33.1 μmol (95 C1: 27.1–11.7 nmol) and 9.2 nmol (95% CI: 7.9–12.3 nmol) for isoflurane, rocuranium and vecuronium, respectively. Coapplication of isoflurane significantly enhanced the inhibitory effects of rocuranium and vecuronium, and it was especially so at low concentration of NMDRs. Isoflurane increases the potency of NDMRs, possibly by enhancing antagonist affinity at the receptor site.

Keywords

isoflurane / non-depolarizing muscle relaxants / cell membrane / cholinergic receptors

References

[1] DilgerJ P, VidalA M, ModyH, et al. . Evidence for direct actions of general anesthesia on an ion channel protein: a new look at a unified mechanism of action. Anesthesiology, 1994, 81: 431-431

[2] ChangeuxJ P, BenoitP, BesisA, et al. . The acetylcholine receptor: functional architecture and regulation. Adv Second Messenger Phosphoprotein Res, 1990, 24: 15-15

[3] SineS M, ClaudioT. Gamma- and delta-subunits regulate the affinity and the cooperativity of ligand binding to the acetylcholine receptor. J Biol Chem, 1991, 266: 19369-19369

[4] FormanS A, MillerK W, YellenG. A discrete site for general anesthetics on a postsynaptic receptor. Mol Pharmacol, 1995, 48: 574-574